Misplaced Pages

Icatibant: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 08:46, 22 January 2024 editCitation bot (talk | contribs)Bots5,459,934 edits Added s2cid. | Use this bot. Report bugs. | Suggested by Abductive | Category:Multiple chemicals in Infobox drug | #UCB_Category 552/623← Previous edit Latest revision as of 05:15, 15 September 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,333 edits refs, links, templates 
Line 1: Line 1:
{{Short description|Pharmaceutical drug}} {{Short description|Pharmaceutical drug}}
{{Use dmy dates|date=April 2020}} {{Use dmy dates|date=April 2020}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
Line 6: Line 7:
| verifiedrevid = 461936569 | verifiedrevid = 461936569
| image = Icatibant.svg | image = Icatibant.svg
| width = 300px | width = 300
| alt = | alt =
| caption = | caption =
Line 14: Line 15:
| Drugs.com = {{drugs.com|monograph|icatibant-acetate}} | Drugs.com = {{drugs.com|monograph|icatibant-acetate}}
| MedlinePlus = | MedlinePlus =
| licence_EU = yes
| DailyMedID = Icatibant | DailyMedID = Icatibant
| licence_US = Icatibant
| pregnancy_AU = C | pregnancy_AU = C
| pregnancy_category = | pregnancy_category =
Line 25: Line 24:


| legal_AU = S4 | legal_AU = S4
| legal_AU_comment = <ref>https://www.tga.gov.au/resources/prescription-medicines-registrations/icatibant-wkt-wockhardt-bio-pty-ltd</ref>
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
Line 80: Line 80:
Icatibant received ] status in Australia, the EU, Switzerland, and the US for the treatment of hereditary angioedema (HAE).<ref>{{cite journal | vauthors = Longhurst HJ | title = Management of acute attacks of hereditary angioedema: potential role of icatibant | journal = Vascular Health and Risk Management | volume = 6 | pages = 795–802 | date = September 2010 | pmid = 20859548 | pmc = 2941790 | doi = 10.2147/vhrm.s4332 | doi-access = free }}</ref> Icatibant received ] status in Australia, the EU, Switzerland, and the US for the treatment of hereditary angioedema (HAE).<ref>{{cite journal | vauthors = Longhurst HJ | title = Management of acute attacks of hereditary angioedema: potential role of icatibant | journal = Vascular Health and Risk Management | volume = 6 | pages = 795–802 | date = September 2010 | pmid = 20859548 | pmc = 2941790 | doi = 10.2147/vhrm.s4332 | doi-access = free }}</ref>


In the EU, the approval by the European Commission (July 2008) allows ] to market Firazyr in the European Union's 27 member states, as well as Switzerland, Liechtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of HAE.<ref name="Jerini2008"/> In the US, the drug was granted FDA approval on August 25, 2011.<ref>{{cite press release|url=http://www.shire.com/shireplc/en/media/shirenews?id=520 |title=FDA Approves Shire's Firazyr (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) |publisher=Shire |access-date=2011-08-28}}</ref> In the EU, the approval by the European Commission (July 2008) allows ] to market Firazyr in the European Union's 27 member states, as well as Switzerland, Liechtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of hereditary angioedema.<ref name="Jerini2008"/> In the US, the drug was granted FDA approval in August 2011.<ref>{{cite press release|url=http://www.shire.com/shireplc/en/media/shirenews?id=520 |title=FDA Approves Shire's Firazyr (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) |publisher=Shire |access-date=2011-08-28}}</ref>


== References == == References ==
{{Reflist}} {{Reflist}}

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/icatibant | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Icatibant }}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/icatibant%20acetate | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Icatibant acetate }}


{{Other hematological agents}} {{Other hematological agents}}
{{Portal bar | Medicine}} {{Portal bar | Medicine}}
{{Authority control}}


] ]

Latest revision as of 05:15, 15 September 2024

Pharmaceutical drug

Pharmaceutical compound
Icatibant
Clinical data
Trade namesFirazyr
Other namesHoe 140, JE 049
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: C
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • (2S)-2-amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC59H89N19O13S
Molar mass1304.54 g·mol
3D model (JSmol)
SMILES
  • C1CC2(C1)C(N2C(=O)3CC4=CC=CC=C4CN3C(=O)(CO)NC(=O)(CC5=CC=CS5)NC(=O)CNC(=O)6C(CN6C(=O)7CCCN7C(=O)(CCCN=C(N)N)NC(=O)(CCCN=C(N)N)N)O)C(=O)N(CCCN=C(N)N)C(=O)O
InChI
  • InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
  • Key:QURWXBZNHXJZBE-SKXRKSCCSA-N
  (what is this?)  (verify)

Icatibant, sold under the brand name Firazyr, is a medication for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. It is not effective in angioedema caused by medication from the ACE inhibitor class.

It is a peptidomimetic consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors.

Mechanism of action

Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, dilates blood vessels and causes smooth muscle cells to contract. Bradykinin plays an important role as the mediator of pain. Surplus bradykinin is responsible for the typical symptoms of inflammation, such as swelling, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Little is known about the effects of icatibant on the bradykinin B1 receptor.

Society and culture

Legal status

Icatibant received orphan drug status in Australia, the EU, Switzerland, and the US for the treatment of hereditary angioedema (HAE).

In the EU, the approval by the European Commission (July 2008) allows Jerini to market Firazyr in the European Union's 27 member states, as well as Switzerland, Liechtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of hereditary angioedema. In the US, the drug was granted FDA approval in August 2011.

References

  1. "Icatibant: HOE 140, JE 049, JE049". Drugs in R&D. 5 (6): 343–8. 2004. doi:10.2165/00126839-200405060-00006. PMID 15563238. S2CID 25491021.
  2. https://www.tga.gov.au/resources/prescription-medicines-registrations/icatibant-wkt-wockhardt-bio-pty-ltd
  3. ^ "Firazyr- icatibant acetate injection, solution". DailyMed. 16 December 2019. Retrieved 17 April 2020.
  4. ^ "Firazyr EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
  5. ^ "Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE" (Press release). Jerini AG. 15 July 2008. Retrieved 22 July 2008.
  6. Sinert R, Levy P, Bernstein JA, Body R, Sivilotti ML, Moellman J, et al. (September–October 2017). "Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema". The Journal of Allergy and Clinical Immunology. In Practice. 5 (5): 1402–1409.e3. doi:10.1016/j.jaip.2017.03.003. PMID 28552382.{{cite journal}}: CS1 maint: overridden setting (link)
  7. Longhurst HJ (September 2010). "Management of acute attacks of hereditary angioedema: potential role of icatibant". Vascular Health and Risk Management. 6: 795–802. doi:10.2147/vhrm.s4332. PMC 2941790. PMID 20859548.
  8. "FDA Approves Shire's Firazyr (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)" (Press release). Shire. Retrieved 28 August 2011.
Other hematological agents (B06)
Enzymes (B06AA)
Drugs used in hereditary
angioedema (B06AC)
Drugs used in sickle cell disease
and beta thalassemia (B06AX)
Others
Portal: Categories:
Icatibant: Difference between revisions Add topic